Thromboxane ligands without blood clotting side effects

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C549S397000, C549S463000, C560S116000, C560S120000, C564S138000, C564S454000

Reexamination Certificate

active

07019149

ABSTRACT:
A method of treating ocular hypotension, hypertension, hemorrhage, myocardial ischemia, angina pectoris, coronary contraction, cerebrovascular contraction after subarachnoidal hemorrhage, cerebral hemorrhage and asthma which comprises administering to a mammal suffering therefrom a therapeutically effective amount of a thromboxane ligand which is a compound formula I,wherein Y is (CH2)x; Z is selected from the group consisting ofand (CR2)x, x is an integer of 1 or 2; n is 0 or 1; R2is hydrogen or an alkyl radical of from 1 to 4 carbons; A is an alkylene or alkenylene radical having from two to seven carbon atoms, which radical may be substituted with one or more hydroxy, oxo, alkyloxy or alkylcarboxy groups or said alkylene or alkenylene may have one or more enchained oxa or imino radicals; B is a methyl radical or a cycloalkyl radical having from three to seven carbon atoms, or an aryl radical, selected from the group consisting of hydrocarbyl aryl and heteroaryl radicals wherein the heteroatom is selected from the group consisting of nitrogen, oxygen and sulfur atoms, or substituted derivatives of said methyl, cycloalkyl or aryl radicals wherein said substituent is selected from the group consisting of halo, nitro, amino, thiol, hydroxy, alkyloxy and alkylcarboxy; and X is selected from the group consisting of nitro, cyano, —COOR, —CH2OR1, —C(O)N(R1)2, —CH2N(R1)2—CH═N—OH and —CH2SR1radicals wherein R is a C1to C10alkyl, phenyl or benzyl and R1is R or hydrogen; or a pharmaceutically acceptable salt thereof.

REFERENCES:
patent: 4436934 (1984-03-01), Larock
patent: 4599353 (1986-07-01), Bito
patent: 4622339 (1986-11-01), Lieb et al.
patent: 4654357 (1987-03-01), Nakane
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5416106 (1995-05-01), Burk et al.
patent: 5516791 (1996-05-01), Burk et al.
Starr. M.S., “Further Studies on the Effect of Prostalgnadin on Intraocular Pressure in the Rabbit”,Exp. Eye Research, 1971, 11, pp. 170-177.
Bito, L.Z., “Prostaglandins, Other Eicosanoids, and Their Derivatives as Potential Antiglaucoma Agents,”Applied Pharmacology in the Medical Treatment of GlaucomasDrance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp. 477-505.
Nilsson, et.al., “ PGF2αIncreases Uveoscleral Outflow”,Invest. Ophthalmol. Vis. Sci.(suppl), pp. 284, 1987.
Siebold, et.al., “ Esterified prostaglandiin shows 'potentí´promise”,Prodrug 5pp. 3, 1989.
Bito, L.Z., “Prostaglandins, Old Concepts and New Perspectives”,Arch. Ophthalmol. 105,pp. 1036, 1987.
Coleman, R.A., et al, “Comparison of the Actions of U-46619, A Prostaglandiin H2-Analogue, with Those of Prostagland H2and Thromboxane A2on some isolated Smooth Muscle Preparations”, Br. J. Pharmacol. 73: pp. 773-778.
Burk et al; “A Safe and Efficient Method For Conversion of 1,2- and 1,3-Diols to Cyclic Carbonates Utilizing Triphosgene”, Tetrahedron Letters, vol. 34, No. 3, pp. 395-398, 1993.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Thromboxane ligands without blood clotting side effects does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thromboxane ligands without blood clotting side effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thromboxane ligands without blood clotting side effects will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3602621

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.